UNSPSC 51434949: Hydrochlorothiazide/telmisartan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class CV400. This VA Drug Class (CV400) classifies this compound as belonging to the group ANTIHYPERTENSIVE COMBINATIONS.

UNSPSC 51434949 Hydrochlorothiazide/telmisartan is a Commodity code representing individual pharmaceutical products, and recent state and local procurement activity under it shows government agencies and public safety entities sourcing emergency and chronic-disease medications through competitive bid and cooperative purchasing mechanisms. The City of Tampa, Texas Health and Human Services Commission, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) are procuring medications including advanced life support drugs, generic multi-source pharmaceuticals, and over-the-counter products for use across fire rescue operations, pharmacy benefit programs, and distributed state and local government facilities. Issuing bodies span city purchasing departments (Tampa), state health agencies (Texas HHS), and cooperative purchasing alliances serving multiple jurisdictions (MMCAP). Vendors must meet FDA compliance, Good Manufacturing Practices certification, Drug Supply Chain Security Act (DSCSA) standards, maintain expiration-date minimums (typically nine months to one year from delivery or manufacture), and provide Safety Data Sheets and accessibility documentation where required. Pricing is the dominant evaluation criterion in recent solicitations, with administrative fees, EDI capability, and manufacturing location detail also weighted in some cases.

Activity spans Florida, Texas, and the upper Midwest (Minnesota and Oregon through MMCAP). The most recent opportunity is the City of Tampa's April 2026 sealed-bid solicitation (26P00188) for advanced life support medications including Labetalol HCI, Epinephrine, Adenosine, and Diltiazem for Tampa Fire Rescue, with an estimated contract value of $40,000 and a response deadline of April 8, 2026; the bid included a 5 percent discount for Small Local Business Enterprise (SLBE) participation. Texas HHS posted Request for Information HHS0017013 on April 3, 2026, to gather vendor capabilities for a future Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program, indicating early-stage market research rather than immediate procurement. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued a Request for Proposal (S1070000015802) due March 26, 2026, for generic multi-source pharmaceuticals and OTC products, with awards effective July 1, 2026, requiring vendor participation through authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson) and a 3 percent administrative fee structure.